Coronary disease & ACSCohort study
Coronary Sinus Narrowing for Treating Refractory Angina
- Prospective observational study
- nonrandomized
- multicentre
- "real-world"
- 25 centres in 9 European countries
Authors' conclusion
The complete primary endpoint analysis of the REDUCER-I study shows patients with refractory angina were safely and effectively treated with the CS Reducer.
Study context
- Population
- Patients with refractory angina treated with the coronary sinus (CS) Reducer
- Participants
- 400 patients
- Outcome
- Improvement in CCS class
- Follow-up
- 6 months
Main finding
As reported in the abstract
Improvement by ≥1 CCS class
Patients improved by ≥1 Canadian Cardiovascular Society (CCS) class
69.8% (240/344)
Observational data: associations, not effects.
Further findings
6-minute walk distance improvement · 6 months
- Improvement in 6-minute walk distance (P < 0.0001)
- 34.1 ± 85.8 m
CCS class and Seattle Angina Questionnaire quality of life · 3 years
- Improvements sustained
- P < 0.0001
- interim 3-year results
Deaths within 30 days
- No deaths within 30 days
Safety
MACE through 30 days
- MACE rate
- 1.6% (95% CI: 0.7-3.6)
Device- or procedure-related serious adverse events through 30 days
- Serious adverse event rate
- 1.1% (4/371)
Original publication
Coronary Sinus Narrowing for Treating Refractory Angina. JACC Cardiovasc Interv. Published 6 November 2024. doi:10.1016/j.jcin.2024.08.047
Summarised from the published abstract; every number is checked against it